Stock Loses 47% in After-Hours Trading
- BioVie shares hit all-time low after proposed public offering
- Shares fell by 47% in the after-hours market
- Company developing drug therapies for liver disease and neurological disorders
Shares of BioVie, a company developing drug therapies for advanced liver disease and neurological disorders, fell to an all-time low on Monday after announcing plans for a public offering. The stock dropped by 47% in the after-hours market, reaching $1.46 from its day’s closing price of $2.80. This marks a 77% loss year-to-date.
Factuality Level: 8
Factuality Justification: The article provides accurate information about the company’s stock performance and its focus on developing drug therapies for specific conditions.
Noise Level: 3
Noise Justification: The article provides relevant information about a company’s stock performance and its business focus but lacks in-depth analysis or context on the reasons behind the drop in share prices or the implications for the industry or investors.
Public Companies: BioVie (BIVI)
Key People: Stephen Nakrosis (Author)
Financial Relevance: Yes
Financial Markets Impacted: BioVie’s stock price
Financial Rating Justification: The article discusses the impact of a public offering on BioVie’s stock price, which is a financial topic related to company performance and market value.
Presence Of Extreme Event: No
Nature Of Extreme Event: No
Impact Rating Of The Extreme Event: No
Extreme Rating Justification: There is no mention of an extreme event in the text.
Move Size: 47%
Sector: Healthcare
Direction: Down
Magnitude: Large
Affected Instruments: Stocks
www.marketwatch.com 
